Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539465 | 0.88 | PPARD (0.41) | PPARDPPARGPPARATAAR1 | |
| SCHEMBL6540355 | 0.84 | PPARD (0.48) | PPARDPPARGPPARACYP19A1CDK2 | |
| SCHEMBL6538813 | 0.83 | PPARD (0.43) | PPARDPPARGPPARACYP19A1CDK2 | |
| SCHEMBL6539585 | 0.82 | PPARD (0.41) | PPARDSLC22A12PPARGPPARATAAR1 | |
| SCHEMBL6539707 | 0.82 | PPARD (0.44) | PPARDPPARGPPARACYP19A1CDK2 | |
| SCHEMBL6539881 | 0.81 | PPARD (0.51) | PPARDPPARGPPARACYP19A1CDK2 | |
| SCHEMBL6256472 | 0.81 | PPARD (0.41) | PPARDSLC22A12PPARGPPARATAAR1 | |
| SCHEMBL6539910 | 0.80 | PPARD (0.41) | PPARDCYP19A1CDK2GSK3BTAAR1 | |
| SCHEMBL6539044 | 0.80 | PPARD (0.44) | PPARDSLC22A12PPARGPPARACYP19A1 | |
| SCHEMBL6539024 | 0.80 | PPARD (0.43) | PPARDPPARGPPARACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885SLC22A12 1616/4885PPARG 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.